Black Diamond Financial LLC Grows Position in CEL-SCI Co. (NYSE:CVM)

Black Diamond Financial LLC lifted its position in shares of CEL-SCI Co. (NYSE:CVM) by 35.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,000 shares of the company’s stock after purchasing an additional 19,000 shares during the quarter. Black Diamond Financial LLC’s holdings in CEL-SCI were worth $84,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CVM. Tidal Investments LLC purchased a new stake in CEL-SCI during the first quarter worth $27,000. Chilton Capital Management LLC raised its position in shares of CEL-SCI by 297.4% in the first quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock worth $31,000 after acquiring an additional 12,200 shares during the period. Forthright Family Wealth Advisory LLC purchased a new stake in shares of CEL-SCI during the 4th quarter worth about $45,000. Cutter & CO Brokerage Inc. grew its holdings in CEL-SCI by 29.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock valued at $126,000 after purchasing an additional 24,634 shares during the period. Finally, Thoroughbred Financial Services LLC grew its stake in CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after acquiring an additional 80,001 shares during the period. 12.08% of the stock is owned by hedge funds and other institutional investors.

CEL-SCI Stock Up 6.7 %

CVM stock opened at $1.28 on Monday. The stock has a market capitalization of $69.32 million, a P/E ratio of -2.03 and a beta of 0.66. CEL-SCI Co. has a 52 week low of $1.02 and a 52 week high of $3.23. The firm has a 50-day simple moving average of $1.19 and a 200-day simple moving average of $1.42. The company has a quick ratio of 0.18, a current ratio of 0.64 and a debt-to-equity ratio of 1.00.

CEL-SCI (NYSE:CVM) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Equities analysts forecast that CEL-SCI Co. will post -0.52 earnings per share for the current fiscal year.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.